UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/583,370	06/18/2007	Michel Dreano	SCHIAFFONATI 1	8192
	7590 02/26/200 D NEIMARK, P.L.L.C	EXAMINER		
624 NINTH ST		MERTZ, PREMA MARIA		
SUITE 300 WASHINGTO	N, DC 20001-5303	ART UNIT	PAPER NUMBER	
			1646	
			MAIL DATE	DELIVERY MODE
			02/26/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/583,370	DREANO ET AL.		
Examiner	Art Unit		
Prema M. Mertz	1646		

	Prema M. Mertz	1646				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress			
THE REPLY FILED <u>12 February 2009</u> FAILS TO PLACE THIS.		-				
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apperfor Continued Examination (RCE) in compliance with 37 C periods:	the same day as filing a Notice of Areplies: (1) an amendment, affidavioal (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request			
a) The period for reply expires 5 months from the mailing date	of the final rejection.					
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire a Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE ').	g date of the final rejection FIRST REPLY WAS FII	n. LED WITHIN TWO			
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of hortened statutory period for reply origi	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as			
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the				
	out prior to the data of filing a brief	will not be entered be	201100			
3. ☐ The proposed amendment(s) filed after a final rejection, k (a) ☐ They raise new issues that would require further cor (b) ☐ They raise the issue of new matter (see NOTE below	nsideration and/or search (see NOา		cause			
(c) ☐ They are not deemed to place the application in beti	**	ducing or simplifying tl	ne issues for			
(d) They present additional claims without canceling a c NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1)		ected claims.				
4. The amendments are not in compliance with 37 CFR 1.12	. ,,	mpliant Amendment (PTOL-324).			
5. Applicant's reply has overcome the following rejection(s):						
6. Newly proposed or amended claim(s) would be all non-allowable claim(s).		timely filed amendmer	nt canceling the			
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prove The status of the claim(s) is (or will be) as follows:		l be entered and an e	kplanation of			
Claim(s) allowed: Claim(s) objected to:						
Claim(s) rejected: <u>19,21-23,25,28,31,32,40,41,43-46,48,5</u> Claim(s) withdrawn from consideration: <u>33-36</u> .	0,53-55 and 57-62.					
AFFIDAVIT OR OTHER EVIDENCE						
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 						
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appea and was not earlier presented. Se	al and/or appellant fail ee 37 CFR 41.33(d)(1	s to provide a).			
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.			
11. The request for reconsideration has been considered but	does NOT place the application in	condition for allowan	ce because:			
12. Note the attached Information <i>Disclosure Statement</i> (s). (PTO/SB/08) Paper No(s) 13. Other:						
	/Prema Mertz/ Primary Examiner					

Continuation of 3. NOTE: The 35 USC 112, first paragraph, scope of enablement rejection over claims 19, 21-23, 25, 28, 31-32, 40, 41, 43-46, 48, 50, 53-55, 57-62, is being maintained for reasons of record as set forth in pages 3-8 of the previous office action of 5/1/08 and pages 3-5 of the previous office action of 9/12/08. Applicantsargue that the present calims are not directed to preventing liver cirrhosis but rather are directed to treating liver cirrhosis regardless of what factors caused the disease. However, contrary to Applicants arguments, the instant specification is only enabling for treatment of chemical cirrhosis and not for immune hepatitis or other autoimmune liver disease.

Claims 19, 21-23, 25, 28, 31-32, 40-41, 43-46, 48, 50, 53-55, 57-62, are rejected under 35 U.S.C.103(a) as being unpatentable over Kovalovich et al. (2001). Applicants argue that Kovalich does not teach treating liver injury with IL-6, Kovalovich describes previous studies where pretreatment with IL-6 prior to CCI4-induced injury and apoptosis protected against liver injury (page 26605, near the bottom of the right column), Kovalovich's own experiments use a pretreatment of IL-6 20 minutes prior to intraperitoneal injection with Jo-2 mAb (an agonistic antibody to the Fas receptor which directly causes hepatic injury by stimulating the apoptotic cell death program) to determine if IL-6 exerts its protective effect on the liver through modulation of the apoptotic cell death program (page 26606, left column, first

full paragraph, and sentence bridging pages 26606 and 26607), and therefore, accordingly, Kovalovich is not directed to treating with IL-6 after cirrhosis induced by CC14 (pretreatment is not the same as treatment after the occurrence of disease). However, contrary to Applicants arguments, if Kovalich taught treating liver cirrhosis with IL-6 after the occurrence of the disease, this rejection would be a 35 USC 102(b) rejection rather than a 35 USC 103(a) rejection. Therefore, the teachings in Kovalovich render obvious the instant invention.